

SUPPLEMENTAL TABLES 1 and 2

Breast Cancer ^{18}F -ISO-1 Uptake as a Marker of Proliferation Status.

Elizabeth S. McDonald, MD, PhD^{1*}, Robert K. Doot, PhD^{1*}, Anthony J. Young, BS¹, Erin K. Schubert, BS¹, Julia Tchou, MD, PhD², Daniel A. Pryma, MD¹, Michael D. Farwell, MD¹, Anupma Nayak, MBBS, MD³, Amy Ziober³, Michael D. Feldman, MD, PhD³, Angela DeMichele, MD⁴, Amy S. Clark, MD⁴, Payal D. Shah, MD⁴, Hsiaoju Lee, PhD¹, Sean D. Carlin, PhD¹, Robert H. Mach, PhD¹, David A. Mankoff, MD, PhD¹

Author affiliations: ¹Department of Radiology, ²Department of Surgery, ³Department of Pathology and Laboratory Medicine, ⁴Department of Medicine, Perelman School of Medicine, University of Pennsylvania

*Contributed equally to this work as co-first authors.

SUPPLEMENTAL TABLE 1. Tumor SUV and SUV-to-Background Ratios

Patient ID	SUV _{max} (g/mL)	SUV _{max} /NBr* Unitless	SUV _{max} /NM [†] Unitless	DVR [‡] Unitless	PVC [§] SUV _{max} (g/mL)
1	2.61	2.12	1.40	1.87	2.77
2	2.02	2.21	1.57	2.08	2.22
3	1.78	1.65	1.11	1.43	1.97
4	2.21	1.59	1.16	1.42	3.43
5	1.55	1.93	0.88	1.79	1.81
6	1.56	1.86	1.45	1.77	1.92
7	2.09	2.84	2.19	2.35	2.27
8	1.31	1.04	0.60	0.91	1.42
10	2.10	3.98	3.56	3.68	2.45
11	1.80	1.14	0.85	0.77	1.83
12	2.01	2.47	2.18	2.11	2.16
13	2.57	1.54	0.98	1.46	2.78
14	3.11	4.38	3.58	4.46	4.87
14b	1.53	2.16	1.76	2.01	2.90
15	1.46	1.77	0.95	1.63	1.53
16	2.56	2.66	1.46	2.49	2.74
17	1.92	2.24	2.24	2.06	2.16
18	1.39	1.46	1.18	1.22	1.44
19	2.72	3.47	1.95	2.81	3.04
20	1.73	2.20	1.80	1.89	1.83
21	2.59	1.85	0.82	1.64	2.72
22	2.16	1.68	0.97	1.54	2.26
23	2.20	2.27	1.67	2.00	2.34
24	1.38	1.66	1.12	1.50	1.69
25	1.79	1.65	1.48	1.61	1.91
26	1.36	2.18	1.57	1.88	2.71
27	1.29	1.29	0.73	1.06	3.34
28	3.04	2.97	1.85	2.58	3.27
29	<u>3.25</u>	<u>4.63</u>	<u>3.08</u>	<u>3.83</u>	<u>3.54</u>
Mean:	2.04	2.24	1.59	1.99	2.46
Median:	2.01	2.12	1.46	1.87	2.27
Standard deviation:	0.57	0.91	0.78	0.84	0.76

*Normal contralateral breast (NBr).

[†]Normal left latissimus dorsi muscle (NM).[‡]Distribution volume ratio (DVR).[§]Partial volume corrected (PVC).

SUPPLEMENTAL TABLE 2: Patient Ki-67 and Tumor Histology

Patient ID	K-67 (%)	MTD [mm]	Type	Receptor	Grade
1	73.90	33.67	IDC [†]	TN [‡]	3
2	23.23	19.67	IDC [†]	ER+ [§]	2
3	21.80	17.67	IDC [†]	HER2+	3
4	3.40	11.67	ILC [¶]	ER+ [§]	N/A
5	27.58	16.67	IDC [†]	ER+ [§]	3
6	8.38	15.33	IDC [†]	ER+ [§]	2
7	47.45	22.00	IDC [†]	ER+ [§]	3
8	3.37	10.00	ILC [¶]	ER+ [§]	1
10	15.75	18.67	M [#]	ER+ [§]	2
11	27.11	25.67	M [#]	ER+ [§]	2
12	15.88	23.33	IDC [†]	HER2+	3
13	26.56	18.33	IDC [†]	ER+ [§]	3
14	14.06	14.00	M [#]	ER+ [§]	2
14b	9.82	11.33	ILC [¶]	ER+ [§]	2
15	11.25	47.33	IDC [†]	ER+ [§]	2
16	30.94	27.33	IDC [†]	HER2+	2
17	4.69	18.67	IDC [†]	ER+ [§]	3
18	16.15	24.33	IDC [†]	ER+ [§]	3
19	31.96	20.33	IDC [†]	ER+ [§]	2
20	15.95	29.00	IDC [†]	TN [‡]	2
21	53.84	27.33	IDC [†]	ER+ [§]	3
22	9.11	54.33	IDC [†]	HER2+	2
23	73.26	26.00	IDC [†]	TN [‡]	2
24	1.94	15.00	M [#]	ER+ [§]	2
25	2.84	20.00	IDC [†]	ER+ [§]	1
26	23.63	11.00	IDC [†]	HER2+	2
27	5.62	7.33	ILC [¶]	ER+ [§]	2
28	20.36	36.33	IDC [†]	ER+ [§]	3
29	<u>20.40</u>	<u>81.00</u>	IDC [†]	TN [‡]	3
Mean:	22.08	24.25			
Median:	16.15	20.00			
Standard deviation:	19.00	15.19			

*Mean tumor diameter (MTD).

[†]Invasive Ductal Carcinoma (IDC).[‡]Triple negative breast cancer (TN).[§]Estrogen receptor positive (ER+).^{||}Human epidermal growth factor receptor 2 (HER2+).[¶]Invasive lobular carcinoma (ILC).[#]Mixture of IDC and ILC (M).